Indeed, when used as single or combinatorial agents, antibodies blocking CTLA-4, PD-1, PD-L1, and other checkpoint molecules activate anti-tumor T cells and have had success in the clinic for the treatment of skin and lung cancers among others, significantly extending the lives of patients [126,127,128,129,130]. This evidence concerns the gene CTLA4 and neoplasm.